Bio Nova Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.10 M
- Paid Up Capital ₹ 0.91 M
- Company Age 45 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.00 M
- Revenue Growth -42.55%
- Profit Growth -307.47%
- Ebitda -208.40%
- Net Worth -9.85%
- Total Assets -14.35%
About Bio Nova Pharmaceuticals
Bio Nova Pharmaceuticals Pvt Ltd (BNPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 October 1979 and has a history of 45 years and four months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 0.91 M.
The company has closed loans amounting to ₹1.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Girish Shahi and Alpana Shahi serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74899DL1979PTC009956
- Company No.
009956
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Oct 1979
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Bio Nova Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Shahi  | Director | 25-Oct-1979 | Current |
| Alpana Shahi | Director | 30-Mar-2015 | Current |
Financial Performance of Bio Nova Pharmaceuticals.
Bio Nova Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 42.55% decrease. The company also saw a substantial fall in profitability, with a 307.47% decrease in profit. The company's net worth dipped by a decrease of 9.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio Nova Pharmaceuticals?
In 2022, Bio Nova Pharmaceuticals had a public holding of 0.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹0
Satisfied Charges
₹1.00 M
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Mar 1995 | Syndicate Bank | ₹1.00 M | Satisfied |
How Many Employees Work at Bio Nova Pharmaceuticals?
Bio Nova Pharmaceuticals has a workforce of 29 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio Nova Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio Nova Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
